ClinicalTrials.gg
WithdrawnNCT04810351FUOUpdated May 4, 2026

Fever of Unknown Origin (FUO) in Elderly Patients

An observational study in Fever of Unknown Origin, sponsored by Universitair Ziekenhuis Brussel. Withdrawn at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Universitair Ziekenhuis Brussel · Observational

How we know

Why this study was withdrawn
Not working anymore at this hospital

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

Objective: Fever of unknown (FUO) origin remains challenging in geriatric patients. Geriatric patients have a blunted immune response responsible for altered fever mechanisms and immune cells responses. Consequently, FUO could be inappropriately named and could be changed in Inflammation of unknown origin (IUO) in this specific population. Furthermore, the studies of FUO in this group are (out)dated and the diagnostic methods have evolved achieving a better sensitivity and specificity. The aim of our study is to assess the spectrum of diseases responsible of FUO or IUO in elderly patients compared to younger patients and to define the diagnostic approach using new diagnostic investigations. The second aim of our study is to assess the usefulness of inflammatory markers, demographic data and comorbidity to differentiate the cause of FUO/IUO.

Design: Patients with FUO or IUO will prospectively be recruited at the geriatric unit and the internal medicine unit of the UZ hospital during four years. The demographic, social and medical data will be screened. All diagnostic methods will be described.

Read the detailed description

Until today, diagnose of fever of unknown origin remains challenging in elderly patients. The presentation of the disease is often atypical and this can delay diagnose and treatment. Geriatric patients have a blunted immune response responsible for altered fever mechanisms. For example, thirty-two percent of geriatric patients presented an infection at the emergency service having no pyrexia or increased white blood cell count in the presence of an infection.

Consequently, the definition of FUO in older patients is different from younger patients. FUO in older patients is defined as tympanic or axillar fever > 37.2.0C, a rectal fever more than 37.50C or a change of > 1.3 centigrade from basal temperature during more than 3 weeks. Furthermore, the name FUO is probably not appropriate in this population and should be replaced with inflammation of unknown origin. However, Unger et al also proposed inflammation of unknown origin in a younger population.

Knockaert et al have shown that the causes of FUO are different in older patients compared to young patients. The causes of FUO are more frequently found in older patients (> 65 years old) compared to younger patients (87-95% and 79% respectively). One explanation is the atypical presentation of classic diseases in geriatric patients. Infection, multi-system diseases and neoplasms were the most prevalent causes. These studies are old and the sensitivity and specificity of the diagnostic methods used presently, such as FDG-Pet-CT, have changed. The spectrum of diseases responsible of FUO or IUO in older patients could therefore have changed since the Knockaert studies. These new diagnostic methods allow better diagnose but also faster diagnose. Consequently the definition of FUO can become obsolete in the field of the duration of the fever.

Materials and Methods

The design of the study is an observational prospective study which will start in juli 2021 until open date in function of the number of included patient (at least 50 patients in both groups).

Patients will be recruited at the geriatric unit and internal medicine unit or geriatric outpatient clinic or internal medicine outpatient clinic of UZ Brussel and will be followed during one year.

The outpatient clinic patients will be recruited during the consultation; the patients who are hospitalized will be recruited during the first week of hospitalization.

The exclusion criteria are the impossibility to have an informed consent from the patient of a representative of the patient. Neutropenia, HIV or nosocomial fever of unknown origins are excluded. Immunodepressed patients are also excluded.

Patients:

All subjects will be screened for underlying illnesses by direct questioning, medical archives and blood sampling. Social evaluation will include determination of age, gender, home (private versus institution), and marital status. Clinical data will comprise: smoking and alcohol habits, old work, hobbies, travel, animal's owner, pneumococcal and influenza vaccine status, allergy, Body mass index (BMI), medical history, current treatment and reasons for hospitalization, recent antibiotic or corticoid treatment. For the older patients (> 70 years old) we will perform a CGA to identify comorbidity and common geriatric conditions. The polypathology and the severity of the medical problems will be scored using the "Charlson comorbidity Index"15 and "Cumulative Illness Rating Scale-Geriatric" (CIRS-G). It is an instrument to quantify disease burden. It comprises a comprehensive review of medical problems of 14 organ systems. It is based on a 0 to 4 rating of each organ system. The "Geriatric Depression Scale" will be used to assess the probability of depressed mood (GDS-15) in 15 questions. The assessment of "Activities of Daily Living" (ADL) will be made by using Katz's scale. It includes the following items: bathing, dressing, transfer, toilet, continence and eating. Each task is graded on a 3-level scale (1 to 3 for Katz's scale), where lower levels represent the absence of dependence and upper level the maximal dependence for the task. Cognitive functions will be assessed using the "Mini Mental State Examination" (MMSE). Possible scores range from 0 to 30 points, with lower scores indicating impaired cognitive function. Nutritional status was assessed using the "Mini Nutritional Assessment" (MNA). A score ≥ 24 identifies patients with a good nutritional status. Scores between 17 and 23.5 identify patients at risk of malnutrition. These latter patients have not yet started to lose weight and do not show low plasma albumin levels but have lower protein-caloric intakes than recommended. A score \< 17 indicates protein-caloric malnutrition. Pain will be assess using a visual analogical scale from 0 to 10 points.

Methods

All diagnostic method means from the standard care of the patients during the hospital stay performed for the assessment of the fever or inflammatory syndrome will be collected:

  • biological analyses, (such as CRP, renal function, lever function, electrolytes, sedimentation rates, uric acid, TSH, vitamin B12, folic acid, 25(OH) vitamin D, hemoglobin, hematocrit, proteins, albumin, white blood cells and formula, creatinine clearance (Cockcroft and de Gault formula), autoimmune assessment, viral or bacterial serology,…
  • urine analyses
  • Bacterial culture or PCR, viral PCR test in body fluids.
  • Pleural puncture
  • Lumbar puncture
  • body sonography
  • body X-rays and tomography
  • Pet Ct
  • Temporal artery biopsy
  • Tissue biopsy
  • Bronchoscopy
  • Laparoscopy
  • Bone marrow aspirate
  • ….

Statistics:

Description statistics will be used such as means, medians, standard deviation and interquartile ranges.

Confidentiality All data will be collected by the investigators. The data will be collected in a way that patient names will not appear in the database (Redcap) and that individual patients will not be recognized by the examination of the collected data. Each patients will receive a code to preserve the anonymization. This code is a nummer that will be record on a listing of patients participating to the study in KWS. The listing in KWS is recorded in the worklisting CGER and is named FUO. Each investigator will be responsible of the anonymization of his/her recruiting. The database will only be accessible by the investigators and protected in Redcap by a password. The database (Excel) will be saved on UZBrussel server (CGER) in a folder named FUO.

02

Conditions studied

  • Fever of Unknown Origin

Keywords

  • FUO
  • Fever of unknown origin
03

In context

Fever of Unknown Origin

21 studies on the registry are indexed under Fever of Unknown Origin; 2 are open to participants now.

Browse Fever of Unknown Origin studies →

Lead sponsor

Universitair Ziekenhuis Brussel is the lead sponsor of 375 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be recruited at the geriatric unit and internal medicine unit or geriatric outpatient clinic of UZ Brussel and will be followed during one year.

Cfr inclusion and exclusion criteria

Eligibility criteria

Inclusion criteria

  • fever during more than one week out of hospital or more than 3 weeks with an intelligent appropriate workup
  • an inflammatory syndrome during more than one week out of hospital or more than 3 weeks out of hospital
  • The exclusion criteria :
  • no inform consent
  • Age \< 18 years old
  • Neutropenia, or nosocomial fever of unknown origins are excluded. Immunodepressed patients are also excluded.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • Younger 1

    young patients ( 18-69 years old) with oral or rectal fever \> 37°8 or tympanic fever \> 37°2 or CRP \> 30 mg/dl during more than one week but less than three weeks of hospital with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever

    Other: observational study

  • Older 1

    old patients ( \> 70 years old) with oral or rectal fever \> 37°8 or tympanic fever \> 37°2 or CRP \> 30 mg/dl during more than one week but less than three weeks out of hospital with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever

    Other: observational study

  • Young 2

    young patients (18-69 years old) with oral or rectal fever \> 37°8 or tympanic fever \> 37°2 or CRP \> 30 mg/dl during more than 3 weeks with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever.

    Other: observational study

  • Older 2

    old patients ( \> 70 years old) with oral or rectal fever fever \> 37°8 or tympanic fever \> 37°2 or CRP \> 30 mg/dl during 3 weeks with appropriate intelligent standard inpatient or outpatient workup to rule out usual causes of fever13 .

    Other: observational study

Interventions

  • Otherobservational study

    There is no intervention. It is an observational study

06

What researchers measure

Primary outcomes

  1. the spectrum of diseases responsible of FUO or IUO

    The proportion of infectious diseases, of neoplasm, of multi system disease of pulmonary embolism or deep vein thrombosis, of intoxication door medication will be measured in both groups

    Time frame: through study completion, an average of 1 year

  2. definition of FUO

    we would like to compare fever of unknown origin since three weeks with fever of unknown origin since one week

    Time frame: through study completion, an average of 1 year

  3. Diagnostic approach of FUO

    To describe the diagnostic approach and compare these diagnostic test in young and old population.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Factors which influence FUO

    Univariate and multivariate analyses will be used to measure the influence of age (years), gender, marital status, current treatment, comorbidities, recent use of antibiotics or corticoïd, Comprehensive geriatric assesment (MMSE, MNA, Katz, Lawton, CIRS-G, Charlson Index, GDS) on the cause of fever of unknown origin in both groups.

    Time frame: At baseline

07

Study locations

1 site
  • UZ brussel
    Brussels, Jette 1090, Belgium
08

References and documents

Publications

  • Norman DC. Fever in the elderly. Clin Infect Dis. 2000 Jul;31(1):148-51. doi: 10.1086/313896. Epub 2000 Jul 25. PubMed 10913413 ↗
  • Norman DC, Yoshikawa TT. Fever in the elderly. Infect Dis Clin North Am. 1996 Mar;10(1):93-9. doi: 10.1016/s0891-5520(05)70288-9. PubMed 8698997 ↗
  • Tal S, Guller V, Gurevich A. Fever of unknown origin in older adults. Clin Geriatr Med. 2007 Aug;23(3):649-68, viii. doi: 10.1016/j.cger.2007.03.004. PubMed 17631239 ↗
  • Tal S, Guller V, Gurevich A, Levi S. Fever of unknown origin in the elderly. J Intern Med. 2002 Oct;252(4):295-304. doi: 10.1046/j.1365-2796.2002.01042.x. PubMed 12366602 ↗
  • Norman DC, Wong MB, Yoshikawa TT. Fever of unknown origin in older persons. Infect Dis Clin North Am. 2007 Dec;21(4):937-45, viii. doi: 10.1016/j.idc.2007.09.003. PubMed 18061083 ↗
  • Vanderschueren S, Del Biondo E, Ruttens D, Van Boxelaer I, Wauters E, Knockaert DD. Inflammation of unknown origin versus fever of unknown origin: two of a kind. Eur J Intern Med. 2009 Jul;20(4):415-8. doi: 10.1016/j.ejim.2009.01.002. Epub 2009 Feb 1. PubMed 19524186 ↗
  • Knockaert DC, Vanneste LJ, Bobbaers HJ. Fever of unknown origin in elderly patients. J Am Geriatr Soc. 1993 Nov;41(11):1187-92. doi: 10.1111/j.1532-5415.1993.tb07301.x. PubMed 8227892 ↗
  • Woolery WA, Franco FR. Fever of unknown origin: keys to determining the etiology in older patients. Geriatrics. 2004 Oct;59(10):41-5. PubMed 15508555 ↗
  • Gafter-Gvili A, Raibman S, Grossman A, Avni T, Paul M, Leibovici L, Tadmor B, Groshar D, Bernstine H. [18F]FDG-PET/CT for the diagnosis of patients with fever of unknown origin. QJM. 2015 Apr;108(4):289-98. doi: 10.1093/qjmed/hcu193. Epub 2014 Sep 9. PubMed 25208896 ↗
  • Schonau V, Vogel K, Englbrecht M, Wacker J, Schmidt D, Manger B, Kuwert T, Schett G. The value of 18F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study. Ann Rheum Dis. 2018 Jan;77(1):70-77. doi: 10.1136/annrheumdis-2017-211687. Epub 2017 Sep 19. PubMed 28928271 ↗
  • Mardi D, Fwity B, Lobmann R, Ambrosch A. Mean cell volume of neutrophils and monocytes compared with C-reactive protein, interleukin-6 and white blood cell count for prediction of sepsis and nonsystemic bacterial infections. Int J Lab Hematol. 2010 Aug 1;32(4):410-8. doi: 10.1111/j.1751-553X.2009.01202.x. Epub 2009 Nov 16. PubMed 19919621 ↗
  • Fusco FM, Pisapia R, Nardiello S, Cicala SD, Gaeta GB, Brancaccio G. Fever of unknown origin (FUO): which are the factors influencing the final diagnosis? A 2005-2015 systematic review. BMC Infect Dis. 2019 Jul 22;19(1):653. doi: 10.1186/s12879-019-4285-8. PubMed 31331269 ↗

Individual participant data

Plan to share: No — No plan

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2023, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 22, 2021
StartActual
Oct 1, 2021
Primary completionActual
Dec 31, 2023
CompletionActual
Dec 31, 2023
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04810351
Responsible party
Nathalie compté (Clinic head of geriatric unit, Universitair Ziekenhuis Brussel) — Principal investigator
First posted
Mar 22, 2021
Start date
Oct 1, 2021
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Last update
May 4, 2026

Study contacts

Nathalie Compte, MD, PhD
principal investigator · Universitair Ziekenhuis Brussel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion